---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-096389"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:51:10.725669+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aileron reports Q4 net loss $7.3M; expects LTI-03 topline results in Q3 2024

## Summary
- Net loss Q4 2023 $7.3M ($1.54 per share) vs $4.5M ($1.00) in Q4 2022; FY 2023 net loss $3.42 per share vs $6.02.
- Cash, cash equivalents and investments $17.3M at Dec 31, 2023; runway into Q4 2024.
- Completed merger with Lung Therapeutics in Oct 2023; raised ~$18M in private placement.
- Appointed Brian Windsor as President and CEO in March 2024 (ex-CEO of Lung).
- LTI-03 Phase 1b topline results in IPF expected Q3 2024.

## SEC filing metadata
- accession: 0001193125-24-096389
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/0001193125-24-096389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/d817402d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-096389
- JSON: https://secwatch.observer/filing/0001193125-24-096389.json
- Plain text: https://secwatch.observer/filing/0001193125-24-096389.txt

## Key facts
- Earnings Releases
  Rein Therapeutics, Inc. reported full year ended December 31, 2023 results: EPS $3.42 per share.
  - Period: full year ended December 31, 2023
  - EPS: $3.42 per share
  - Result: reported results
  source text: The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/0001193125-24-096389-index.htm
- Earnings Releases
  Rein Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income $7.3 million, EPS $1.54 per share.
  - Period: the fourth quarter ended December 31, 2023
  - Net income: $7.3 million
  - EPS: $1.54 per share
  - Result: reported results
  source text: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022. The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/0001193125-24-096389-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.